Morgan Stanley Rapt Therapeutics, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 372,421 shares of RAPT stock, worth $4.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

372,421

Previous 435,835 14.55%

Holding current value

$4.06 Million

Previous $688,000 34.01%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.05 - $1.72 $66,584 - $109,072	-63,414 Reduced 14.55%	372,421 $454,000
Q4 2024 Feb 14, 2025	BUY	$0.81 - $3.1 $104,165 - $398,656	128,599 Added 41.86%	435,835 $688,000
Q3 2024 May 14, 2025	SELL	$1.76 - $3.75 $1.53 Million - $3.27 Million	-871,659 Reduced 73.94%	307,236 $617,000
Q3 2024 Nov 14, 2024	SELL	$1.76 - $3.75 $1.53 Million - $3.27 Million	-871,659 Reduced 73.94%	307,236 $617,000
Q2 2024 May 14, 2025	BUY	$2.89 - $9.38 $2.15 Million - $6.97 Million	743,060 Added 170.49%	1,178,895 $3.6 Million
Q2 2024 Oct 17, 2024	SELL	$2.89 - $9.38 $2.1 Million - $6.81 Million	-726,439 Reduced 38.13%	1,178,895 $3.6 Million
Q2 2024 Aug 14, 2024	SELL	$2.89 - $9.38 $2.1 Million - $6.81 Million	-726,439 Reduced 38.13%	1,178,895 $3.6 Million
Q1 2024 Oct 17, 2024	BUY	$6.87 - $26.45 $4.99 Million - $19.2 Million	726,439 Added 61.62%	1,905,334 $17.1 Million
Q1 2024 Aug 16, 2024	BUY	$6.87 - $26.45 $5.91 Million - $22.7 Million	859,999 Added 82.27%	1,905,334 $17.1 Million
Q1 2024 May 15, 2024	BUY	$6.87 - $26.45 $5.91 Million - $22.7 Million	859,999 Added 82.27%	1,905,334 $17.1 Million
Q4 2023 Aug 16, 2024	SELL	$11.28 - $25.46 $1.51 Million - $3.4 Million	-133,560 Reduced 11.33%	1,045,335 $26 Million
Q4 2023 Feb 13, 2024	BUY	$11.28 - $25.46 $3.2 Million - $7.22 Million	283,427 Added 37.2%	1,045,335 $26 Million
Q3 2023 Nov 15, 2023	SELL	$16.34 - $24.66 $2.18 Million - $3.28 Million	-133,118 Reduced 14.87%	761,908 $12.7 Million
Q2 2023 Aug 14, 2023	BUY	$16.06 - $21.61 $1.94 Million - $2.61 Million	120,851 Added 15.61%	895,026 $16.7 Million
Q1 2023 May 15, 2023	BUY	$17.19 - $30.8 $274,868 - $492,492	15,990 Added 2.11%	774,175 $14.2 Million
Q4 2022 Feb 14, 2023	SELL	$16.28 - $24.6 $229,385 - $346,614	-14,090 Reduced 1.82%	758,185 $15 Million
Q3 2022 Nov 14, 2022	SELL	$17.96 - $30.46 $4.87 Million - $8.26 Million	-271,277 Reduced 26.0%	772,275 $18.6 Million
Q2 2022 Oct 27, 2022	SELL	$10.26 - $23.59 $127,275 - $292,633	-12,405 Reduced 1.17%	1,043,552 $19 Million
Q2 2022 Aug 15, 2022	SELL	$10.26 - $23.59 $127,275 - $292,633	-12,405 Reduced 1.17%	1,043,552 $19 Million
Q1 2022 Oct 27, 2022	BUY	$17.02 - $40.22 $211,133 - $498,929	12,405 Added 1.19%	1,055,957 $23.2 Million
Q1 2022 May 13, 2022	BUY	$17.02 - $40.22 $954,549 - $2.26 Million	56,084 Added 5.61%	1,055,957 $23.2 Million
Q4 2021 Feb 14, 2022	BUY	$29.5 - $39.5 $6.97 Million - $9.33 Million	236,129 Added 30.92%	999,873 $36.7 Million
Q3 2021 Nov 15, 2021	BUY	$29.86 - $39.47 $22.8 Million - $30.1 Million	763,744 New	763,744 $23.7 Million

Others Institutions Holding RAPT

# of Institutions

Shares Held

7.02M

Call Options Held

Put Options Held

View Full List

About RAPT Therapeutics, Inc.

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $323M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

More about RAPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account